Bryan D. Fleming

481 total citations
9 papers, 379 citations indexed

About

Bryan D. Fleming is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Biotechnology. According to data from OpenAlex, Bryan D. Fleming has authored 9 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Biotechnology. Recurrent topics in Bryan D. Fleming's work include Monoclonal and Polyclonal Antibodies Research (5 papers), Toxin Mechanisms and Immunotoxins (5 papers) and Transgenic Plants and Applications (3 papers). Bryan D. Fleming is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (5 papers), Toxin Mechanisms and Immunotoxins (5 papers) and Transgenic Plants and Applications (3 papers). Bryan D. Fleming collaborates with scholars based in United States, India and Germany. Bryan D. Fleming's co-authors include David M. Mosser, Mitchell Ho, He-jiao Bian, Ying Fu, Martin F. Flajnik, Tim F. Greten, Matthew D. Hall, Xiaolin Wu, Thomas Longerich and Mingqian Feng and has published in prestigious journals such as Hepatology, Cancer Research and European Journal of Immunology.

In The Last Decade

Bryan D. Fleming

9 papers receiving 373 citations

Peers

Countries citing papers authored by Bryan D. Fleming

Since Specialization

Citations

This map shows the geographic impact of Bryan D. Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan D. Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan D. Fleming more than expected).

Fields of papers citing papers by Bryan D. Fleming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan D. Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan D. Fleming. The network helps show where Bryan D. Fleming may publish in the future.

Co-authorship network of co-authors of Bryan D. Fleming

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan D. Fleming. A scholar is included among the top collaborators of Bryan D. Fleming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan D. Fleming. Bryan D. Fleming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Generation of Single-Domain Antibody-Based Recombinant Immunotoxins 2022 ·Methods in molecular biology ·Bryan D. Fleming, Mitchell Ho	3
2	Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update 2020 ·Biomolecules ·Bryan D. Fleming, Mitchell Ho	12
3	Engineered Anti‐GPC3 Immunotoxin, HN3‐ABD‐T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention 2019 ·Hepatology ·Bryan D. Fleming, Daniel J. Urban, Matthew D. Hall, Thomas Longerich, Tim F. Greten, Ira Pastan, Mitchell Ho	47
4	Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks 2018 ·PubMed ·Mingqian Feng, He-jiao Bian, Xiaolin Wu, Tianyun Fu, Ying Fu, Jessica Hong, Bryan D. Fleming, Martin F. Flajnik, Mitchell Ho	62
5	Abstract 59: Engineering glypican-3 targeting immunotoxins for the treatment of liver cancer 2017 ·Cancer Research ·Bryan D. Fleming, (unknown), Ira Pastan, Mitchell Ho	1
6	Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer 2016 ·Toxins ·Bryan D. Fleming, Mitchell Ho	24
7	Upregulated IL-1β in dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages 2015 ·Skeletal Muscle ·Tatiana V. Cohen, Gina M. Many, Bryan D. Fleming, Viola F. Gnocchi, Svetlana Ghimbovschi, David M. Mosser, Eric P. Hoffman, Terence A. Partridge	25
8	The generation of macrophages with anti-inflammatory activity in the absence of STAT6 signaling 2015 ·Journal of Leukocyte Biology ·Bryan D. Fleming, Prabha Chandrasekaran, Laura A. L. Dillon, Elizabeth Dalby, Rahul Suresh, Arup Sarkar, Najib M. El-Sayed, David M. Mosser	40
9	Regulatory macrophages: Setting the Threshold for Therapy 2011 ·European Journal of Immunology ·Bryan D. Fleming, David M. Mosser	165

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact